Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression

Blood

Volumn 92, Issue 1, 1998, Pages 101-107

  Mori, Takehiko ^b   Nishimura, Takashi ^b   Ikeda, Yasuo ^b   Hotta, Tomomitsu ^b   Yagita, Hideo ^b   Ando, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA; FAS ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LYMPHOCYTE TRANSFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032127448     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.101.413k14_101_107     Document Type: Article

References (34)

1. Brubaker DB: Immunopathogenic mechanism of posttransfusion graft-vs-host disease. Proc Soc Exp Biol Med 202:122, 1993
2. Korngold R, Sprent J: Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med 197:12, 1991
3. Kelemen E, Szebeni J, Petranyi GG: Graft-versus-host disease in bone marrow transplantation: Experimental, laboratory, and clinical contributions of the last few years. Int Arch Allergy Immunol 102:309, 1993
4. Anderson KC, Weinstein HJ: Trans fusion-associated graft-versus-host disease, N Engl J Med 323:315, 1990
5. Ferrara JL, Deeg HJ: Graft-versus-host disease, N Engl J Med 324:667, 1991
6. + T-cell clones. Blood 89:1440, 1997
7. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
8. Nash RA, Storb R: Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 8:674, 1996
9. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195, 1996
10. Gleichmann E, Van Elven EH, Van der Veen JPW: A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperration. Preferential formation of autoantibodies characteristic of SLE. Eur J Immunol 12:152, 1982
11. Via CS, Sharrow SO, Shearer GM: Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-versus-host disease. J Immunol 139:1840, 1987
12. Pickel K, Hoffman MK: Suppressor T cells arising in mice undergoing a graft-versus-hoit response. J Immunol 118:653, 1977
13. Rus V, Svetic A, Nguyen P, Gause WC, Via CS: Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol 155:2396, 1995
14. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 23:333, 1993
15. Mori T, Ando K, Tanaka K, Ikeda Y, Koga Y: Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalocirus, Blood 89:3565, 1997
16. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364:806, 1993
17. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, Yagita H: Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 94:3914, 1997
18. Maciejewski J, Selleri C, Anderson S, Young NS: Fas antigen expression on CD34; human marrow cells is induced by interferonγ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3138, 1995
19. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okumura T, Gondo H, Niho Y: Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 86:883, 1995
20. Stalder T, Hahn S, Erb P: Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 152:1127, 1994
21. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Nishikawa S, Miura Y, Suda T: Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood 78:1706, 1991
22. Baker MB, Altman NH, Podack ER, Levy RB; The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation im mice. J Exp Med 183:2645, 1996
23. Piguet PF, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/cachectin is an effetor of skin and gut lesion of the acute phase of graft-vs-host disease. J Exp Med 166:1280, 1987
24. Piguet PF: GVHR elicited by products of class I or class II loci of the MHC: Analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy. J Immunol 135:1637, 1985
25. Hakim FT, Shearer GM: Immunological and hematopoietic deficiencies of graft-vs-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs-Host Disease. New York, NY, Dekker, 1990
26. Hakim FT, Sharrow SO, Payne S, Shearer GM: Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice infected with parental lymphocytes. J Immunol 146:2108, 1991
27. Sprent J, Surh CD, Agus D, Hurd M, Sutton S, Heath WR: Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J Exp Med 180:307, 1994
28. Hong DS, Beckham C, Huss R, Lee JW, Hockenbery D, Ledbetter JA, Deeg HJ: Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow culture involves apoptosis and is prevented by c-kit ligand. Blood 86:3341, 1995
29. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
30. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage. J Immunol 154:3806, 1995
31. Aguila HL, Weissman IL: Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells. Blood 87:1225, 1996
32. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992
33. Nishimura T, Sadata A, Yahagi C, Santa K, Otsuki K, Watanabe K, Yahata T, Habu S: The therapeutic effect of interleukin-12 or its antagonist in transplantation immunity. Ann NY Acad Sci 795:371, 1996
34. Selleri C, Sato T, Vecchio LD, Luciano L, Barrett AJ, Rotole B, Young NS, Maciejewski JP: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-αin chronic myeloid leukemia. Blood 89:957, 1997